Skip to main content

6th Hellenic Congress of Oncology Cover

.blurhash-client-img { display: none !important; }

6th Hellenic Congress of Oncology

Forum of Clinical Oncology

Volume 13 (2022): Issue 2 (December 2022)

Open Access

|Apr 2023

Figures & tables

Figures & Tables

The variation of PTEN, P-PTEN and DJ-1 biomarker levels in oncology patients before and during immunotherapy depends on the corresponding levels in healthy adults.

The variation of the DJ-1 biomarker levels regarding the histological type of the cancer before and after performing immunotherapy.

The variation of the levels of the PTEN biomarker regarding the histological type of the neoplasm before and after performing the immunotherapy.

The variation of P-PTEN biomarker levels with respect to the histological type of the neoplasm prior and during immunotherapy.

The variation of PTEN, P-PTEN AND DJ1 biomarker levels with respect to sex in cancer patients and healthy adults.

RFS according to HER2 expression

N- patients

N+ patients

Patients with ductal carcinoma

Patients with lobular / mixed ductal&lobular carcinoma

Localization of transfected DJ-1-GFP in HeLa cells. Nuclei were stained with PI.

Localization of transfected DJ-1-GFP in U87 cells. Nuclei were stained with PI.

Localization of transfected DJ-1-GFP in MCF-7 cells. Nuclei were stained with PI.

Western blotting analysis, using an anti-E-Cadherin monoclonal antibody, of extracts from MCF-7 cells that were incubated for the indicated time periods with the culture supernatants of GFP- or GFP-DJ1-overexpressed HeLa cells.

Western blotting analysis, using an anti-B-Catenin monoclonal antibody, of extracts from MCF-7 cells that were incubated for the indicated time periods with the culture supernatants of GFP- or GFP-DJ1-overexpressed HeLa cells.

j_fco-2022-0009_tab_006

		HER2-Surgery
		HER2-0	HER2-1	HER2-2neg	HER2-2pos	HER2+3
HER2-core	HER2-0	71.1%	26.8%	1.4%	0.7%	0.0%
	HER2-1	12.9%	66.9%	17.3%	1.4%	1.4%
	HER2-2neg	10.0%	35.0%	50.0%	5.0%	0.0%
	HER2-2pos	0.0%	0.0%	0.0%	100.0%	0.0%
	HER2+2-ND	10.0%	20.0%	65.0%	5.0%	0.0%
	HER2+3	0.0%	13.3%	6.7%	20.0%	60.0%

j_fco-2022-0009_tab_005

HER2-neg to HER2-pos	7 out of 138	5.1%
HER2-0 to HER2-low	10 out of 40	25.0%

j_fco-2022-0009_tab_008

Sarcoma type	site of primary	sex	age	stage	site of NGS	mutation	line of targeted treatment	drug	duration
ES	Big toe foot	Male	39	metastatic	metastasis	RAD50, BRCA2	4th	Olaparib	2,5 months
uLPS	ampulla of Vater	Female	77	metastatic	metastasis	CHEK2	2nd	Olaparib	1 month
MPNST	unknown primary tumor	Male	48	metastatic	metastasis	BRAF	1st	Dabrafenib/Trametinib	12 months
IFT	abdomen	Female	68	local	Primary tumor	ALK	1st	crizotinib	6 months ongoing
ERMS	jaw	Male	22	lung	metastasis	BRCA1	7th	olaparib	1 month

Clinicopathological characteristics of patients

	Median (25^th–75^th perc)	Missing (%)
Total	1470	38 (2,6%)
Age	59 (18 – 94)
Date of Diagnosis	01/01/1994–30/12/2018
Stage	1416	54 (3,7%)
I	218 (15,4%)
II	119 (8,4%)
IIIa	39 (2,8%)
IIIb	58 (4,1%)
IIIc	774 (54,7%)
IV	208 (14,7%)
Histology	1419	51 (3,4%)
Serous	894 (63%)
Mucinous	77 (5,4%)
Clear cell	114 (8%)
Endometrioid	163 (11,5%)
Poorly differentiated	55 (3,6%)
Other	116 (8,2%)
Grade	1224	246 (16,7%)
Low (G1)	99 (8%)	246 (16,7%)
High
BRCA 1/2 mutations	92 (6,3%)
Present	27 (29,3%)
Absent	65 (70,7%)
Not tested	1378 (93,7%)
Surgery	1463	7 (0,4%)
PDS	1254 (85,7%)
IDS	124 (8,5%)
None	84 (5,7%)
ECOG	1340	130 (8,8%)
0	891 (66,5%)
I	253 (17,2%)
II	123 (9,2%)
III	61 (4,6%)
IV	11 (0,8%)
	989	481 (32,7%)
Median PFS (months)	37,9
Median PFS - IIIC	27,5
Median PFS - IV	24,63
Median PFS - IIIC/IV	26,89
	1447	23 (1,6%)
Median OS (months)	52,04
Median OS - IIIC	45,16
Median OS - IV	31,98
Median OS – IIIC/IV	42,36

j_fco-2022-0009_tab_007

HER2-neg to HER2-pos	7 out of 301	2.3%
HER2-0 to HER2-low	40 out of 142	28.2%

j_fco-2022-0009_tab_002

		CHEMOTHERAPY COST	COST PER PATIENT	NUMBER OF PATIENTS	COST PER SESSION	AVG No SESSIONS	AVG AGE	ΓYNAIKEΣ WOMEN	AAAAAA MEN
BREAST CANCER	2007	1.597.695,04 €	10.442,45 €	153	1.316,06 €	7	61	151	2
BREAST CANCER	2016	1.460.909,35 €	10.075,24 €	145	1.295,13 €	7	59,8	142	3
PANCREATIC CANCER	2007	248.681,69 €	5.920 €	42	826,19 €	7	64	13	29
PANCREATIC CANCER	2016	306.121,73 €	3.327,41 €	92	352,67 €	9	65,5	43	49

j_fco-2022-0009_tab_001

Primary tumor	Incidence	Gender (female)	Age≥65	BMI≥30	Smoking	Khorana score ≥2	Metastatic	HRTAs	DDIs
Pancreas	27.2	40.9	54.0	11.2	49.2	100.0	76.7	96.8	63.1
Lung	25.8	22.3	57.6	19.2	88.1	60.5	88.5	89.3	58.2
Stomach	7.1	23.8	57.1	14.3	61.2	98.0	65.9	89.8	32.7
Urological	11.6	9.5	66.3	22.5	71.3	26.3	69.3	66.3	47.5
Rectal	11.1	37.3	59.2	11.8	47.4	21.1	85.5	93.4	30.3
Breast	4.2	96.2	24.1	17.2	34.5	17.2	73.1	62.1	65.5
Ovarian	4.1	100.0	60.7	25.0	28.6	67.9	76.9	85.7	78.6
Corpus uterus	1.2	100.0	62.5	62.5	25.0	62.5	83.3	62.5	87.5
Cervix uterus	0.7	100.0	-	-	80.0	80.0	80.0	100.0	100.0
Other	7.0	32.4	43.8	29.2	66.7	4.2	64.7	83.3	50.0

j_fco-2022-0009_tab_004

		HER2-ResD
		HER2-0	HER2-1	HER2-2neg	HER2-2pos	HER2+3
HER2-core	HER2-0	72.5%	22.5%	2.5%	0.0%	2.5%
	HER2-1	11.1%	73.6%	9.7%	0.0%	5.6%
	HER2-2neg	15.4%	42.3%	34.6%	3.8%	3.8%
	HER2-2pos	0.0%	33.3%	8.3%	50.0%	8.3%
	HER2+3	7.4%	3.7%	3.7%	3.7%	81.5%

Articles in this issue

DOI: https://doi.org/10.2478/fco-2022-0009 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 1 - 59

Published on: Apr 7, 2023

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology

© 2023 , published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 13 (2022): Issue 2 (December 2022)